GMT Genomtec S.A.
Genomtec S.A. researches and develops a mobile point of care genetic testing platform for the clinical diagnostics market in Poland. The company's flagship project is the Genomtec ID, a diagnostic platform that enables the detection of pathogens, such as viruses, bacteria, and fungi, as well as genetic mutations through the analysis of biological material of patients using swabs, urine, and saliva. It also develops SNAAT chemistry for mutation detection in oncology. In addition, the company develops and commercializes tests used in the detection of viral infectious diseases and other areas. Genomtec S.A. was founded in 2016 and is based in Wroclaw, Poland.…
Industry Peers
Medical DevicesKey Statistics
About Genomtec (WSE: GMT)
›
Genomtec (WSE: GMT) is listed on Warsaw Stock Exchange, where its shares trade in PLN. It belongs to the Medical Devices industry, part of the Healthcare sector, and reports about 32 employees.
The shares were at 2.500 PLN on 19 November 2026, down 46.2% over 52 weeks. Its 52-week range is 2.350 PLN to 6.870 PLN: the price is 63.6% below the high and 6.4% above the low.
Its market capitalisation is 42.66M PLN.
Genomtec reports return on equity of -113.2% and revenue up 83.3% year over year.
It holds more cash than debt, a net cash position of 12.60M PLN. Its Piotroski F-score is 4 out of 9, an average reading of its financial health.